InvestSMART

Alterity Therapeutics Limited (ASX: ATH) - Announcements

Current share price for ATH : $0.260 0.02 (8.33%)+

ASX company news and announcements for Alterity Therapeutics Limited (ATH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Alterity Therapeutics Limited (ATH) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Alterity Therapeutics Limited (ATH), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Alterity Therapeutics Limited (ATH)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$60 Alterity to Deliver Oral Presentation of ATH434 Trial at AAN 3 Apr 2025 9:51AM $0.008 $0.260 risen by 3,150%
$60 Results of Meeting 31 Mar 2025 12:13PM $0.009 $0.260 risen by 2,788.89%
$60 Alterity Completes Last Patient Visit in Open-Label Trial 27 Mar 2025 10:41AM $0.010 $0.260 risen by 2,636.84%
$60 Ceasing to be a substantial holder 24 Mar 2025 7:20PM $0.010 $0.260 risen by 2,500%
$60 Application for quotation of securities - ATH 14 Mar 2025 2:06PM $0.010 $0.260 risen by 2,500%
$60 Becoming a substantial holder 13 Mar 2025 7:55PM $0.010 $0.260 risen by 2,500%
$60 Notice of Extraordinary General Meeting/Proxy Form 28 Feb 2025 12:30PM $0.011 $0.260 risen by 2,263.64%
$60 Half Yearly Report and Accounts 28 Feb 2025 12:09PM $0.011 $0.260 risen by 2,263.64%
$60 Proposed issue of securities - ATH 24 Feb 2025 4:07PM $0.012 $0.260 risen by 2,066.67%
$60 Change in substantial holding 19 Feb 2025 8:19AM $0.011 $0.260 risen by 2,263.64%
$60 Notice Under Section 708A 17 Feb 2025 9:15AM $0.011 $0.260 risen by 2,263.64%
$60 Application for quotation of securities - ATH 17 Feb 2025 9:07AM $0.011 $0.260 risen by 2,263.64%
$60 Proposed issue of securities - ATH 10 Feb 2025 10:25AM $0.012 $0.260 risen by 2,066.67%
$60 Alterity raises A$40m to Advance ATH434 Development in MSA 10 Feb 2025 10:23AM $0.012 $0.260 risen by 2,066.67%
$60 Ceasing to be a substantial holder 7 Feb 2025 8:21AM $0.012 $0.260 risen by 2,066.67%
$60 Trading Halt 6 Feb 2025 8:55AM $0.012 $0.260 risen by 2,066.67%
$60 Becoming a substantial holder 6 Feb 2025 8:20AM $0.012 $0.260 risen by 2,066.67%
$60 Disclosure under Takeovers Panel GN 20 5 Feb 2025 2:14PM $0.012 $0.260 risen by 2,066.67%
$60 Change in substantial holding 5 Feb 2025 8:23AM $0.013 $0.260 risen by 1,900%
$60 Notice Under Section 708A 4 Feb 2025 12:00PM $0.014 $0.260 risen by 1,825.93%
$60 Application for quotation of securities - ATH 4 Feb 2025 11:57AM $0.014 $0.260 risen by 1,825.93%
$60 Proposed issue of securities - ATH 3 Feb 2025 9:58AM $0.012 $0.260 risen by 2,066.67%
$60 Alterity Raises Funds for ATH434 BD and Clinical Activities 3 Feb 2025 9:54AM $0.012 $0.260 risen by 2,066.67%
$60 Application for quotation of securities - ATH 30 Jan 2025 5:01PM $0.018 $0.260 risen by 1,344.44%
$60 ATH434-201 Phase 2 Topline Results Presentation 30 Jan 2025 3:34PM $0.018 $0.260 risen by 1,344.44%

151 - 175 of 583 results

Page 7 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.